PTPRC and glioma: Our data show, that compared with isotype treatment, both αTIGIT monotherapy and dual blockade of TIGIT & PD1 significantly reduced the frequencies of GL261 glioma infiltrating MDSCs (CD45+CD11b+Gr1+ cells), most strikingly for αTIGIT/αPD1 combination therapy (Figure 5B).